Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 18,451	$ 43,338,710		$ (15,712,414)	$ 27,644,747
Balance (in Shares) at Dec. 31, 2019	18,450,992
Sale of common stock, net of offering costs	$ 3,048	24,277,235			24,280,283
Sale of common stock, net of offering costs (in Shares)	3,048,654
Issuance of common stock for accrued research and development expense	$ 221	1,131,792			1,132,013
Issuance of common stock for accrued research and development expense (in Shares)	220,666
Issuance of common stock for stock option exercises	$ 285	714,097			714,382
Issuance of common stock for stock option exercises (in Shares)	285,003
Issuance of common stock in connection with cashless warrant exercises	$ 530	(530)
Issuance of common stock in connection with cashless warrant exercises (in Shares)	529,559
Stock-based compensation		2,187,149			2,187,149
Foreign currency translation adjustment			(51,538)		(51,538)
Net loss				(18,567,234)	(18,567,234)
Balance at Dec. 31, 2020	$ 22,535	71,648,453	(51,538)	(34,279,648)	37,339,802
Balance (in Shares) at Dec. 31, 2020	22,534,874
Sale of common stock, net of offering costs	$ 2,140	28,012,879			28,015,019
Sale of common stock, net of offering costs (in Shares)	2,140,000
Issuance of common stock for stock option exercises	$ 252	689,500			689,752
Issuance of common stock for stock option exercises (in Shares)	252,156
Issuance of common stock for warrant exercises	$ 445	179,768			180,213
Issuance of common stock for warrant exercises (in Shares)	444,751
Stock-based compensation		3,548,368			3,548,368
Foreign currency translation adjustment			2,617		2,617
Net loss				(31,038,712)	(31,038,712)
Balance at Dec. 31, 2021	$ 25,372	$ 104,078,968	$ (48,921)	$ (65,318,360)	$ 38,737,059
Balance (in Shares) at Dec. 31, 2021	25,371,781